143 related articles for article (PubMed ID: 38142544)
1. Case report of radiotherapy combined with anlotinib and immunotherapy for a patient with esophageal cancer and esophageal fistula.
He L; Han Q; Zhao M; Ma H; Cheng P; Yang H; Zhao Y
Appl Radiat Isot; 2024 Mar; 205():111162. PubMed ID: 38142544
[TBL] [Abstract][Full Text] [Related]
2. A patient with tracheoesophageal fistula and esophageal cancer after radiotherapy.
Hagendoorn J; Schipper ME; Cloïn A; Ramjankhan FZ; Siersema PD; van Hillegersberg R
Nat Rev Gastroenterol Hepatol; 2010 Dec; 7(12):702-6. PubMed ID: 21063396
[TBL] [Abstract][Full Text] [Related]
3. Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial.
Huang J; Xiao J; Fang W; Lu P; Fan Q; Shu Y; Feng J; Zhang S; Ba Y; Zhao Y; Liu Y; Bai C; Bai Y; Tang Y; Song Y; He J
Cancer Med; 2021 Mar; 10(5):1681-1689. PubMed ID: 33586360
[TBL] [Abstract][Full Text] [Related]
4. Irradiation of carcinoma of the esophagus containing a tracheoesophageal fistula.
Arlington A; Bohorquez J
Cancer; 1993 Jun; 71(12):3808-12. PubMed ID: 8508348
[TBL] [Abstract][Full Text] [Related]
5. [A case of advanced esophageal cancer with suspected tracheoesophageal fistula that responded to chemoradiotherapy].
Shitara K; Munakata M; Ishiguro A; Hoshi Y; Okada R; Tomioka R; Mitobe S; Sakata Y; Ebina A; Aoki M
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1137-41. PubMed ID: 16912535
[TBL] [Abstract][Full Text] [Related]
6. A case report of immune checkpoint inhibitor nivolumab combined with anti-angiogenesis agent anlotinib for advanced esophageal squamous cell carcinoma.
Tang Y; Ou Z; Yao Z; Qiao G
Medicine (Baltimore); 2019 Oct; 98(40):e17164. PubMed ID: 31577707
[TBL] [Abstract][Full Text] [Related]
7. Tracheoesophageal fistula closure after staged dose-escalated radiotherapy for esophageal squamous cell carcinoma: a case report.
Zhen CJ; Zhang P; Bai WW; Song YZ; Qiao XY; Zhou ZG
J Int Med Res; 2023 May; 51(5):3000605231172449. PubMed ID: 37170736
[TBL] [Abstract][Full Text] [Related]
8. Carrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer: A case report.
Liu L; Zhang X; Zhou L; Yang T; Qiao Y; Jiang X
Medicine (Baltimore); 2021 Sep; 100(35):e27138. PubMed ID: 34477165
[TBL] [Abstract][Full Text] [Related]
9. Predictors of post-treatment stenosis in cervical esophageal cancer undergoing high-dose radiotherapy.
Kim JW; Kim TH; Kim JH; Lee IJ
World J Gastroenterol; 2018 Feb; 24(7):862-869. PubMed ID: 29467556
[TBL] [Abstract][Full Text] [Related]
10. Comparative Clinical Efficacy of 'Concurrent Chemoradiotherapy (CCRT) and Anlotinib' Than CCRT in Patients with Locally Advanced ESCC.
Wang G; Beeraka NM; Xiao W; Zhang Y; Xue N; Chen G; Liu J; Liu Y
Technol Cancer Res Treat; 2022; 21():15330338221080939. PubMed ID: 35235470
[No Abstract] [Full Text] [Related]
11. Management of Malignant Tracheoesophageal Fistula.
Shamji FM; Inculet R
Thorac Surg Clin; 2018 Aug; 28(3):393-402. PubMed ID: 30054077
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy of anlotinib plus S-1 as a second-line therapy for recurrent or metastatic esophageal squamous cell carcinoma].
Sun W; Zou X; Zhang W; Hu S; Ge K
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Feb; 41(2):250-255. PubMed ID: 33624599
[TBL] [Abstract][Full Text] [Related]
13. Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma.
Zhang W; Yan C; Gao X; Li X; Cao F; Zhao G; Zhao J; Er P; Zhang T; Chen X; Wang Y; Jiang Y; Wang Q; Zhang B; Qian D; Wang J; Zhou D; Ren X; Yu Z; Zhao L; Yuan Z; Wang P; Pang Q
Oncologist; 2021 Jul; 26(7):e1110-e1124. PubMed ID: 33893689
[TBL] [Abstract][Full Text] [Related]
14. Closure of tracheoesophageal fistulas with chemotherapy and radiotherapy.
Ahmed HF; Hussain MA; Grant CE; Wadleigh RG
Am J Clin Oncol; 1998 Apr; 21(2):177-9. PubMed ID: 9537207
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of camrelizumab combined with radiotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: a prospective single-arm phase II clinical trial protocol.
Chen M; Huang Y; Zhang S; Zeng T; Huang G; Chen C; Zheng B
Trials; 2023 Aug; 24(1):554. PubMed ID: 37626367
[TBL] [Abstract][Full Text] [Related]
16. Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.
Yan Z; Yao ZH; Yao SN; Wang HY; Chu JF; Song M; Zhao S; Liu YY
Immunotherapy; 2020 Nov; 12(16):1161-1166. PubMed ID: 32814482
[No Abstract] [Full Text] [Related]
17. Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Cai J; Zhou S; Luo Y; Liu A
Medicine (Baltimore); 2021 Dec; 100(51):e28126. PubMed ID: 34941058
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in treating oesophageal cancer.
Harada K; Rogers JE; Iwatsuki M; Yamashita K; Baba H; Ajani JA
F1000Res; 2020; 9():. PubMed ID: 33042518
[TBL] [Abstract][Full Text] [Related]
19. Esophageal carcinoma with respiratory tract fistula.
Little AG; Ferguson MK; DeMeester TR; Hoffman PC; Skinner DB
Cancer; 1984 Mar; 53(6):1322-8. PubMed ID: 6198068
[TBL] [Abstract][Full Text] [Related]
20. Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma.
Chen Y; Yu R; Liu Y
Crit Rev Oncol Hematol; 2023 Oct; 190():104115. PubMed ID: 37633347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
